By Doug Young & Rene Vanguestaine

The latest annual survey by the EU Chamber of Commerce in China shows revenue fell for more European businesses’ China operations last year. Is this a watershed moment for China’s economy, showing the days of western enthusiasm for investing in the country will never return to pre-covid levels? And AstraZeneca has become the latest major company to weigh a potential spinoff of its China unit. Is this the beginning of a trend?

About China Inc

China Inc by Bamboo Works discusses the latest developments on Chinese companies listed in Hong Kong and the United States to drive informed decision-making for investors and others interested in this dynamic group of companies.

Subscribe to China Inc on your favorite app:

Apple Podcasts Spotify

Recent Articles

Dongshan Precision launches Hong Kong IPO

Dongshan Precision flat in Hong Kong trading debut

Shares of printed circuit board, precision component and optical module maker Suzhou Dongshan Precision Manufacturing Co. Ltd. (2384.HK; 002384.SZ) opened 5% below their IPO price in their trading debut on…